{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paroxysmal+Nocturnal+Hemoglobinuria+%28PNH%29&page=3",
    "query": {
      "condition": "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 67,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paroxysmal+Nocturnal+Hemoglobinuria+%28PNH%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paroxysmal+Nocturnal+Hemoglobinuria+%28PNH%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T18:47:36.913Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02946463",
      "title": "ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Eculizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 272,
      "start_date": "2016-12-12",
      "completion_date": "2023-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-10-11T18:47:36.913Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Whittier, California • Fort Worth, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02946463"
    },
    {
      "nct_id": "NCT07413679",
      "title": "Long-term Safety of Danicopan: IPIG Registry-based Cohort Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria",
        "PNH"
      ],
      "interventions": [
        {
          "name": "Danicopan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-08-18",
      "completion_date": "2029-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-10-11T18:47:36.913Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07413679"
    },
    {
      "nct_id": "NCT00143559",
      "title": "Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Chronic Myeloid Leukemia",
        "Juvenile Myelomonocytic Leukemia",
        "Myelodysplastic Syndrome",
        "Paroxysmal Nocturnal Hemoglobinuria",
        "Hodgkin's Lymphoma",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Systematic chemotherapy and antibodies",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Miltenyi CliniMACS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 17,
      "start_date": "2005-08",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2009-01-29",
      "last_synced_at": "2026-10-11T18:47:36.913Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00143559"
    },
    {
      "nct_id": "NCT03056040",
      "title": "ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Eculizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2017-05-17",
      "completion_date": "2022-02-21",
      "has_results": true,
      "last_update_posted_date": "2025-03-12",
      "last_synced_at": "2026-10-11T18:47:36.913Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Los Angeles, California • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03056040"
    },
    {
      "nct_id": "NCT05389449",
      "title": "A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria"
      ],
      "interventions": [
        {
          "name": "Danicopan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 80,
      "start_date": "2022-10-28",
      "completion_date": "2026-08-24",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-11T18:47:36.913Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Long Island City",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05389449"
    },
    {
      "nct_id": "NCT01412047",
      "title": "Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria",
        "PNH"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 75,
      "start_date": "2012-03",
      "completion_date": "2013-06-30",
      "has_results": false,
      "last_update_posted_date": "2017-10-18",
      "last_synced_at": "2026-10-11T18:47:36.913Z",
      "location_count": 3,
      "location_summary": "Englewood, Colorado • Weston, Florida • Scarborough, Maine",
      "locations": [
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Scarborough",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01412047"
    },
    {
      "nct_id": "NCT00098280",
      "title": "Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemoglobinuria, Paroxysmal"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 75,
      "start_date": "2004-12",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-11T18:47:36.913Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098280"
    },
    {
      "nct_id": "NCT06326814",
      "title": "A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria"
      ],
      "interventions": [
        {
          "name": "Humanized anti-Factor Bb monoclonal antibody",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-10-11",
      "completion_date": "2023-05-05",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-10-11T18:47:36.913Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06326814"
    },
    {
      "nct_id": "NCT02264639",
      "title": "A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2015-02-23",
      "completion_date": "2018-10-22",
      "has_results": true,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-10-11T18:47:36.913Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Miami Lakes, Florida • Louisville, Kentucky + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02264639"
    },
    {
      "nct_id": "NCT06312644",
      "title": "Study of Ultomiris® (Ravulizumab) Safety in Pregnancy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ultomiris-exposed Pregnant/ Postpartum",
        "Pregnancy",
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
        "Atypical Hemolytic Uremic Syndrome (aHUS)",
        "Generalized Myasthenia Gravis (gMG)",
        "Neuromyelitis Optica Spectrum Disorder (NMOSD)"
      ],
      "interventions": [
        {
          "name": "Ultomiris",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 75,
      "start_date": "2024-12-16",
      "completion_date": "2034-07-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-10-11T18:47:36.913Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06312644"
    }
  ]
}